source
- San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosisSan Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
- Charles River acquires two Frontage bioanalysis labs in Pennsylvania for $470 millionCharles River Laboratories announced it has purchased two laboratory sites from Tigermed’s Frontage in Exton, Pennsylvania, paying $470 million upfront. The labs together span about 150,000 square…